Search for Clinical Trial Results

Sponsored By

Glycogen Storage Disease Type II - 31 Studies Found

Status Study
Withdrawn Study Name: High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease
Condition: Glycogen Storage Disease Type II
Date: 2012-08-01
Interventions: Other: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding
Completed Study Name: A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
Condition: Glycogen Storage Disease Type II
Date: 2004-02-10
Completed Study Name: A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease
Condition: Glycogen Storage Disease Type II
Date: 2003-04-22
Interventions: Biological: Myozyme 20 mg/kg qow or 40mg/kg qow Othe
Completed Study Name: Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602
Condition: Glycogen Storage Disease Type II
Date: 2005-08-01
Interventions: Biological: Myozyme 20 mg/kg qow or 40 mg/kg qow Oth
Recruiting Study Name: Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)
Condition: Glycogen Storage Disease Type II
Date: 2016-06-13
Interventions:
  • Device: RMT therapy using modified RMT device

Recruiting Study Name: Pompe Disease Registry
Condition:
  • Glycogen Storage Disease Type II
  • Pompe Di
    Date: 2005-09-30
Completed Study Name: Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
Condition:
  • Glycogen Storage Disease Type II
  • Glycogen
    Date: 2003-12-23
    Interventions: Biological: Myozyme 20 mg/kg Other Name: Alglucosida
Approved for marketing Study Name: Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease
Condition:
  • Glycogen Storage Disease Type II
  • Glycogen
    Date: 2003-12-23
    Interventions: Biological: alglucosidase alfa 20 mg/kg qow Other Na
Completed Study Name: Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies
Condition:
  • Pompe Disease Infantile-Onset
  • Glycogen St
    Date: 2008-09-30
    Interventions: Biological: Myozyme 10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
Completed Study Name: Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.
Condition:
  • Pompe Disease Late-Onset
  • Glycogen Storage
    Date: 2008-10-02
    Interventions: Biological: Myozyme 30 mg/kg qow f and 40 mg/kg qow
Next >>>